mRNA 5'-End Cap Analogues for Efficient Capping and Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mRNA 5'-end cap analogs have low capping efficiency, leading to unstable and translationally inactive uncapped mRNAs, and can induce an unwanted immune response, with enzymatic treatment required for separation, and reverse incorporation issues.
Innovation Solution
Introduction of tri- or tetra-nucleotide cap analogues with a hydrophobic substituent at the N6-adenosine position, facilitating easy purification of capped mRNAs using chromatographic methods and enhancing translation efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If 2'-O-methyl modifications are introduced to enhance stability, then stability is improved, but immunogenicity is reduced
Solution Approach 1:
The patent applies local quality modification by selectively modifying specific nucleotides within the mRNA sequence. The 2'-O-methyl modifications are introduced at specific positions (particularly in the 5' UTR and coding regions) while leaving other regions unchanged, thereby achieving enhanced stability and reduced immunogenicity without completely altering the mRNA's functional properties
Solution Approach 2:
The patent creates a composite mRNA structure combining modified nucleotides (2'-O-methyl) with unmodified nucleotides. This composite approach allows the mRNA to exhibit both improved stability from the modified portions and maintained translational efficiency from the unmodified portions, while the specific cap analog structure (m7GpppN) provides additional composite benefits
2Object-generated harmful factors
If 5'-end cap structures are modified to reduce immunogenicity, then immunogenicity is reduced, but translation initiation efficiency may be affected
Solution Approach 1:
The patent changes the chemical parameters of the cap structure by introducing a non-canonical base (N) at the 5'-end position and using specific analogs such as m7GpppN, m7GpppA, or m7GpppU instead of the natural m7GpppG cap. These parameter changes reduce immunogenicity while the patent demonstrates that translation initiation efficiency is maintained through optimized selection of these analogs
3Productivity
If canonical m7GpppG cap is used, then translation initiation is efficient, but immunogenicity is high and stability is reduced
Solution Approach 1:
The patent changes the chemical parameters of the cap structure by introducing a non-canonical base (N) at the 5'-end position and using specific analogs such as m7GpppN, m7GpppA, or m7GpppU instead of the natural m7GpppG cap. These parameter changes reduce immunogenicity and enhance stability while maintaining translation initiation efficiency
Solution Approach 2:
The patent creates a composite cap structure combining the methylated guanine (m7G) portion with a modified 5'-end nucleotide (N). This composite cap structure provides the benefits of reduced immunogenicity and enhanced stability from the modified portion while maintaining the translation initiation functionality provided by the m7G component
Data Source
AI summary
The invention relates to new mRNA 5' end cap analogs, RNA molecules containing them, their uses and methods for their in vitro synthesis, as well as a method for protein or peptide synthesis in vitro or in cell cultures, which method encompases translation of the RNA molecule.